Syndax Pharmaceuticals, Inc. Other Receivables
Syndax Pharmaceuticals, Inc. (SNDX) had Other Receivables of $2.70 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Nontrade Receivables
us-gaap:OtherReceivables · last filed 2026-08-04
- 2026-06-30: Other Receivables $2.70M.
- 2026-03-31: Other Receivables $267.00K.
- 2025-12-31: Other Receivables $6.40M.
- 2025-09-30: Other Receivables $0.00.
| Period end | Other Receivables |
|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $267.00K 10-Q · filed 2026-04-30 |
| 2025-12-31 | $6.40M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 |
| 2025-06-30 | $3.63M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $3.59M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $3.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.50M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $3.50M 10-Q · filed 2024-08-01 |
| 2024-04-30 | $3.50M 10-Q · filed 2026-08-04 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |